Daniel C. Javitt, M.D., Ph.D.
Professor of Psychiatry and Neuroscience
Director, Division of Experimental Therapetics,
Department of Psychiatry, Columbia University
Director, Schizophrenia Research,
Nathan Kline Institue for Psychiatric Research
Dr. Javitt’s research focuses on brain mechanisms of psychosis and other severe psychiatric disorders, with special emphasis on the role of brain glutamate systems and N-methyl-D-aspartate (NMDA) –type glutamate receptors in health and disease. Dr. Javitt was among the first to demonstrate a link between NMDA dysfunction and schizophrenia, and has been instrumental in developing glutamatergic theories of schizophrenia over the past 20 years. He was also among the first to test new classes of NMDA-based treatments for schizophrenia, including glycine, D-serine and glycine transport inhibitors, and has more recently initiated studies of NMDA receptor antagonists, such as ketamine and high-dose D-cycloserine in treatment of depression, and of brain stimulation methods, including transcranial direct current stimulation (tDCS) as an adjunct to cognitive remediation.
Dr. Javitt has published over 250 articles on topics relating to normal and abnormal brain function in serious psychiatric illness. He has received awards for his research from numerous organizations, including the American Psychiatric Association, American College of Neuropsychopharmacology, Society for Biological Psychiatry, American College of Psychiatrists and the Child Welfare League of America. His work has also been featured in the PBS special “Prisoners of the Brain,” and Scientific American. His research is supported by the National Institute for Mental Health, the National Institute on Drug Abuse, the Stanley Medical Research Institute, and other philanthropic organizations. He currently serves as associate editor of Schizophrenia Bulletin, and as an editorial board member for several prestigious journals including Schizophrenia Research and the American Journal of Psychiatry. He is a former chair of the NIMH NPAS study section. He is a Fellow of the American College of Neuropsychopharmacology, an advisory board member for the Brain and Behavior Research Foundation and a standing member of the Institute of Medicine Neuro Forum.
Undergraduate: Princeton University, BA, 1975-1979
Medical School: Albert Einstein College of Medicine, MD, 1979-1983
Doctoral Degree: Albert Einstein College of Medicine, PhD (Neuroscience), 1987-1990
Internship: Montefiore Medical Center, Internal Medicine, 1983-1984
Residency: Albert Einstein College of Medicine, Psychiatry, 1984-1987
Fellowship: Albert Einstein College of Medicine, Biological Psychiatry/Neurophysiology, 1987-1990
Board Certifications: Psychiatry
• Brain Stimulation
NYS Psychiatric Institute
Room 5080 Unit/Box:4
1051 Riverside Drive
New York, NY 10032
Dr. Javitt’s research focuses on new treatment development in schizophrenia and other severe psychiatric disorders, with special emphasis on brain glutamatergic systems and N-methyl-D-aspartate (NMDA) –type glutamate receptors, neuropharmacology, and brain stimulation.
1. Javitt DC and Zukin SR: Recent advances in the phencyclidine model of schizophrenia. The American journal of psychiatry. Am J Psychiatry 1991;1401: 1301-8
2. Javitt DC: Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr Opin Drug Disc Dev 2009;12: 468-478
3. Dias EC, Butler PD, Hoptman MJ, Javitt DC: Early Sensory Contributions to Contextual Encoding Deficits in Schizophrenia. Arch Gen Psychiatry 2011;68: 654-664
4. Moghaddam B and Javitt DC: From Revolution to Evolution: The Glutamate Hypothesis of Schizophrenia and its Implication for Treatment. Neuropsychopharmacology 2011;37: 4-15
5. Balla A., Schneider S, Sershen H, Javit DC: Effects of novel, high affinity glycine transport inhibitors on prefrontal dopamine release in a rodent model of schizophrenia. Eur Neuropsychopharmacol in press